Several early phase trials examining safety and efficacy of inhibitors of aberrant EGFR and HER (lapatinib, erlotinib, pertuzumab, trastuzumab) in patients with cholangiocarcinoma and other solid tumors are either pending or have failed to show significant objective treatment response. This evidence concerns the gene EGFR and cholangiocarcinoma.